Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Ligand Pharmaceuticals, Inc.
- Market Cap
- Unavailable
- Volume
- 405.0K
Quote data as of 7:03 AM ET
About
Ligand Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise, primarily engaged in sourcing and advancing innovative technologies. These technologies are instrumental in assisting other pharmaceutical businesses with the identification and progression of new therapeutic solutions. The company's portfolio includes medications such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Ronald M. Evans founded the organization in 1987, and its principal corporate offices are located in San Diego, California.
Quick stats
Shares outstanding20.0M
Computed float18.9M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000886163
Websitehttp://www.ligand.com
AI Summary
AI-generated14d agomajorneutraldebt offeringLigand Announces Closing of Convertible Senior Notes Offering
Ligand Pharmaceuticals closed a $700 million offering of 0.00% convertible senior notes due 2031, generating net proceeds of approximately $678.2 million.
The company allocated about $72.9 million to hedge transactions and repurchased 228,859 shares of common stock for $60.0 million at a price of $262.17 per share to offset potential dilution upon conversion.
Remaining proceeds are earmarked for general corporate purposes and investments, including the previously announced acquisition of XOMA Royalty Corporation.